Table 1 Genomic analysis of undifferentiated embryonal sarcoma of the liver by FoundationOne CDx
Detected somatic mutation | FDA-approved therapeutic options | Clinical significance |
|---|---|---|
TP53(R196*) | Doxorubicin hydrochloride | Sensitivity/response |
Abemaciclib | Resistance | |
STK11(F354L) | Atezolizumab | Resistance |
Nivolumab | Resistance | |
Pembrolizumab | Resistance | |
POLE(K2223R) | – | – |
AXL(P179L) | – | – |
BRIP1(D546G) | – | – |
IKBKE(G660E) | – | – |
MEF2B(A174G) | – | – |
NF2(c.114+1G>A) | – | – |
PARP3(A232_E234del) | – | – |
SNCAIP(T183A) | – | – |
TSC1(A84T) | – | – |